Meridia Risk Management Program Strengthened
This article was originally published in The Pink Sheet Daily
Executive Summary
New patient leaflet and revised labeling highlights the risk profile of Abbott's obesity drug. The risk of a "large increase in blood pressure or heart rate" is "the most important information you should know about Meridia," leaflet says. Thirty-count bottles also approved.
You may also be interested in...
Arava Label Strengthened Following Reports Of Interstitial Lung Disease
Sanofi-Aventis adds stronger warnings for the rheumatoid arthritis drug following post-marketing reports of interstitial lung disease in Japan. Patients should notify their physician and may need to discontinue therapy if pulmonary symptoms develop. Updated labeling also includes geriatric use information.
Abbott's Meridia To Be Packaged With Patient Guide In 30-Count Bottle
The monthly supply bottles will replace existing 100-count bottles to simplify distribution of the new patient leaflet emphasizing the risk of increased blood pressure and heart rate. Meridia is the fourth of seven drugs flagged by FDA safety officer Graham to have safety information strengthened.
Arava Label Strengthened Following Reports Of Interstitial Lung Disease
Sanofi-Aventis adds stronger warnings for the rheumatoid arthritis drug following post-marketing reports of interstitial lung disease in Japan. Patients should notify their physician and may need to discontinue therapy if pulmonary symptoms develop. Updated labeling also includes geriatric use information.